The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Abstract
Background —Studies of the association between the plasma concentration of lipoprotein(a) [Lp(a)] and coronary heart disease (CHD) have reported apparently conflicting findings. We report a meta-analysis of the prospective studies with at least 1 year of follow-up published before 2000. Methods and Results —The following information was abstracted for each study: geographical location of study, size, type of cohort (population-based or selected because of previous disease), mean age, follow-up duration, blood storage temperature and duration, assay methods, degree of adjustment for potential confounders, and relationship of baseline Lp(a) measurement with subsequent CHD risk. There were 5436 deaths from CHD or nonfatal myocardial infarctions during a weighted mean follow-up of 10 years in the 27 eligible studies. Comparison of individuals in the top third of baseline plasma Lp(a) measurements with those in the bottom third in each study yielded a combined risk ratio of 1.6 (95% CI 1.4 to 1.8, 2 P <0.00001), with similar findings when the analyses were restricted to the 18 studies of general populations (combined risk ratio 1.7, 95% CI 1.4 to 1.9; 2 P <0.00001). Despite differences among studies in blood storage techniques and assay methods, there was no significant heterogeneity among the results from the 18 population-based studies or among those from the 9 studies of patients with previous disease. Lp(a) was only weakly correlated with classical vascular risk factors, and adjustment for those that had been recorded made little difference to the reported risk ratios. Conclusions —These prospective studies demonstrate a clear association between Lp(a) and CHD, but further studies are needed to determine the extent to which this is causal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schaefer, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510370051031 · Cited by 487
Cited by
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Ridker, P. M., Buring, J. E., Rifai, N., & Cook, N. R. (2007) · JAMA · doi:10.1001/jama.297.6.611 · Cited by 1,814
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi, B., & Cooper, D. S. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0043 · Cited by 1,418
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.161596 · Cited by 1,360
Goldstein, L. B., Bushnell, C. D., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181fcb238 · Cited by 1,306
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan, R. S. (2006) · Circulation · doi:10.1161/circulationaha.104.482570 · Cited by 1,212
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Salpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00545.x · Cited by 640
Nordestgaard, B. G., & Langsted, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071233 · Cited by 575
Phylogenetic Shadowing of Primate Sequences to Find Functional Regions of the Human Genome
Boffelli, D., McAuliffe, J., Ovcharenko, D., Lewis, K. D., Ovcharenko, I., Pachter, L., & Rubin, E. M. (2003) · Science · doi:10.1126/science.1081331 · Cited by 516
Pischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Stampfer, M. J., & Rimm, E. B. (2005) · Circulation · doi:10.1161/circulationaha.104.532499 · Cited by 514
Mozaffarian, D., & Clarke, R. (2009) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602976 · Cited by 410
Lipoprotein (a) measurements for clinical application
Marcovina, S. M., & Albers, J. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r061648 · Cited by 338
Prospective Study of One Million Deaths in India: Rationale, Design, and Validation Results
Jha, P., Gajalakshmi, V., Gupta, P. C., Kumar, R., Mony, P., Dhingra, N., Peto, R., & Collaborators, R.-C. P. S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0030018 · Cited by 323
Self-citationMarcovina, S. M., Koschinsky, M. L., Albers, J. J., & Skarlatos, S. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.023689 · Cited by 288
Extreme lipoprotein(a) levels and improved cardiovascular risk prediction
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.023 · Cited by 284
Bennet, A. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.6.598 · Cited by 281
Case–control association mapping by proxy using family history of disease
Liu, J. Z., Erlich, Y., & Pickrell, J. K. (2017) · Nature Genetics · doi:10.1038/ng.3766 · Cited by 238
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes
Baxter, J. D., & Webb, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2830 · Cited by 253
Apolipoproteins: metabolic role and clinical biochemistry applications
Dominiczak, M. H., & Caslake, M. J. (2011) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011111 · Cited by 238
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Merki, E., Graham, M. J., Mullick, A. E., Miller, E. R., Crooke, R. M., Pitas, R. E., Witztum, J. L., & Tsimikas, S. (2008) · Circulation · doi:10.1161/circulationaha.108.786822 · Cited by 156
The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity
Tsimikas, S., & Witztum, J. L. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328308b622 · Cited by 138
Langsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1206 · Cited by 136
Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk
Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.049 · Cited by 103
Dyslipidemia and nephrotic syndrome: recent advances.
Kronenberg, F. (2005) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2004.10.003 · Cited by 85
Shapiro, M. D., Minnier, J., Tavori, H., Kassahun, H., Flower, A., Somaratne, R., & Fazio, S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010932 · Cited by 70
Cardiovascular Disease in Women
Stock, E. O., & Redberg, R. (2012) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.07.001 · Cited by 65
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
van Wissen, S., Smilde, T. J., Trip, M. D., de Boo, T., Kastelein, J. J. P., & Stalenhoef, A. F. H. (2003) · Heart · doi:10.1136/heart.89.8.893 · Cited by 58
Hero, M., Ankarberg-Lindgren, C., Taskinen, M.-R., & Dunkel, L. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02226 · Cited by 55
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
Pang, R. W. C., Tam, S., Janus, E. D., Siu, S. T. S., Ma, O. C. K., Lam, T. H., & Lam, K. S. L. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.05.013 · Cited by 20
Enigmatic role of lipoprotein(a) in cardiovascular disease.
Anuurad, E., Enkhmaa, B., & Berglund, L. (2010) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2010.00238.x · Cited by 14
Metadata
- Authors
- Danesh, J., Collins, R., & Peto, R.
- Venue
- Circulation
- Published
- 2000-09-05
- Volume
- 102
- Issue
- 10
- Pages
- 1082-1085
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2130483103
- Cited by
- 938
- References
- 1
- FWCI
- 44.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
